Multiple RTKs, including ERBB3, PDGFRB, EPHA2, TYRO3, FGFR2, and ROR2, have been reported to mediate the therapeutic resistance of HER2+ BC [30–32]. This evidence concerns the gene ERBB2 and breast cancer.